Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma

References

• Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse large B Cell lymphoma. Cell. 2017;171:481–494.e15.
   PubMed Web of Science ®Google Scholar
• Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol. 2013;14:525–533.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Schmitz N, Mounier N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. JCO. 2012;30:4462–4469.
   PubMed Web of Science ®Google Scholar
• Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. JCO. 2014;32:3490–3496.
   PubMed Web of Science ®Google Scholar
• Van Den Neste E, Schmitz N, Mounier N, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2017;52:216–221.
   PubMed Web of Science ®Google Scholar
• Bosly A, Coiffier B, Gisselbrecht C, et al. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. JCO. 1992;10:1615–1623.
   PubMed Web of Science ®Google Scholar
• Mondello P, Steiner N, Willenbacher W, et al. Lenalidomide in relapsed or refractory diffuse large b-cell lymphoma: is it a valid treatment option? Oncologist. 2016;21:1107–1112.
   PubMed Web of Science ®Google Scholar
• Goebeler ME, Knop S, Viardot A, et al. Bispecific T-Cell Engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. JCO. 2016;34:1104–1111.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377:2545–2554.
   PubMed Web of Science ®Google Scholar
• Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. 1990;113:619–627.
   PubMed Web of Science ®Google Scholar
• Smith KA. Interleukin-2: inception, impact, and implications. Science. 1988;240:1169–1176.
   PubMed Web of Science ®Google Scholar
• Katsuya H, Yamanaka T, Ishitsuka K, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. JCO. 2012;30:1635–1640.
   PubMed Web of Science ®Google Scholar
• Tokunaga M, Uto H, Takeuchi S, et al. Newly identified poor prognostic factors for adult T-cell leukemia-lymphoma treated with allogeneic hematopoietic stem cell transplantation. Leukemia & Lymphoma. 2017;58:37–44.
   PubMed Web of Science ®Google Scholar
• Marri PR, Hodge LS, Maurer MJ, et al. Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19:6812.
   PubMed Web of Science ®Google Scholar
• Kusano Y, Yokoyama M, Terui Y, et al. High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy. Blood Cancer J. 2017;7:e614.
   PubMed Web of Science ®Google Scholar
• Umino K, Fujiwara SI, Ikeda T, et al. Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP. Hematology (Amsterdam, Netherlands). 2017;22:521–526.
   PubMed Web of Science ®Google Scholar
• Umino K, Fujiwara SI, Ito S, et al. Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma. Leukemia & Lymphoma. 2017;58:316–323.
   PubMed Web of Science ®Google Scholar
• Kitagawa J, Hara T, Tsurumi H, et al. Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U). J Cancer Res Clin Oncol. 2009;135:53–59.
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Nakamaki T, Abe M, et al. Association of soluble interleukin-2 receptor and C-reactive protein with the efficacy of bendamustine salvage treatment for indolent lymphomas and mantle cell lymphoma. Acta Haematol. 2018;139:12–18.
   PubMed Web of Science ®Google Scholar
• Sonbol MB, Maurer MJ, Stenson MJ, et al. Elevated soluble IL-2Ralpha, IL-8, and MIP-1beta levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma. Am J Hematol. 2014;89:E223–E227.
   PubMed Web of Science ®Google Scholar
• Dlouhy I, Filella X, Rovira J, et al. High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma. Leukemia Res. 2017;59:20–25.
   PubMed Web of Science ®Google Scholar
• Tomita N, Suzuki T, Miyashita K, et al. The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma. Leukemia & Lymphoma. 2016;57:2763–2770.
   PubMed Web of Science ®Google Scholar
• Goto N, Tsurumi H, Goto H, et al. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens. Ann Hematol. 2012;91:705–714.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. JCO. 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48:452–458.
   PubMed Web of Science ®Google Scholar
• Umino K, Fujiwara SI, Sato K, et al. High-dose methotrexate and cytarabine-based multi-agent chemotherapy (Modified Bonn Protocol) for systemic lymphoma with CNS involvement. Acta Haematol. 2017;137:93–99.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Watanabe K, Fukuda T, et al. Prediction of prognosis for patients with diffuse large B-cell lymphoma refractory to or in first relapse after initial R-CHOP therapy: a single-institution study. Anticancer Res. 2017;37:2655–2662.
   PubMed Web of Science ®Google Scholar
• Katoh D, Ochi Y, Yabushita T, et al. Peripheral blood lymphocyte-to-monocyte ratio at relapse predicts outcome for patients with relapsed or refractory diffuse large B-cell lymphoma in the rituximab era. Clin Lymphoma Myeloma Leukemia. 2017;17:e91–e97.
   PubMed Web of Science ®Google Scholar